Zenas BioPharma, Inc.
obexelimab
Systemic Lupus Erythematosus (SLE)
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for obexelimab in Systemic Lupus Erythematosus (SLE) are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Topline results of the Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) expected 4Q 2026”